Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corp (NQ: GERN )

1.860 -0.130 (-6.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Geron Corp

< Previous 1 2 3 4 Next >
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Participate at Upcoming Investor Conferences in November
From Geron Corporation
Via Business Wire
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
From Geron Corporation
Via Business Wire
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
From Geron Corporation
Via Business Wire
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
From Geron Corporation
Via Business Wire
Geron to Participate in the Baird 2023 Global Healthcare Conference
From Geron Corporation
Via Business Wire
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
From Geron Corporation
Via Business Wire
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
From Geron Corporation
Via Business Wire
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Geron Corporation
Via Business Wire
Geron to Host Virtual Investor Event on June 14, 2023
From Geron Corporation
Via Business Wire
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.